

**SUPPLEMENT NO. 4 DATED 1 NOVEMBER 2022 TO THE
OFFERING CIRCULAR DATED 13 MAY 2022**

Bank of America Corporation
(a Delaware (U.S.A.) Corporation)

BofA Finance LLC
(a Delaware Limited Liability Company)

Merrill Lynch B.V.
(a Dutch Private Limited Liability Company)

Merrill Lynch International & Co. C.V.
(a Curaçao Limited Partnership)

NOTE, WARRANT AND CERTIFICATE PROGRAMME

Unconditionally and irrevocably guaranteed
(in respect of Notes issued by BofA Finance LLC and Instruments (other than Secured Instruments)
issued by Merrill Lynch B.V. and Merrill Lynch International & Co. C.V.)

by

Bank of America Corporation

This supplement (the "**Supplement**") constitutes a supplement to the offering circular of Bank of America Corporation ("**BAC**"), BofA Finance LLC ("**BofA Finance**"), Merrill Lynch B.V. ("**MLBV**") and Merrill Lynch International & Co. C.V. ("**MLICo.**") dated 13 May 2022 (the "**Original Offering Circular**") (as supplemented on 19 July 2022, 1 August 2022 and 18 October 2022, the "**Offering Circular**"), prepared in connection with the Note, Warrant and Certificate Programme (the "**Programme**") of BAC, BofA Finance, MLBV and MLICo. Terms defined in the Offering Circular have the same meanings when used in this Supplement.

This Supplement is supplemental to, and shall be read in conjunction with, the Offering Circular. To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Offering Circular by this Supplement and (b) any other statement in or incorporated by reference into the Offering Circular, the statements in (a) above will prevail.

Each of BAC, BofA Finance, MLBV and MLICo. accepts responsibility for the information contained in this Supplement and to the best of the knowledge of BAC, BofA Finance, MLBV and MLICo., the information contained in this Supplement is in accordance with the facts and this Supplement makes no omission likely to affect its import.

Copies of this Supplement and the document incorporated by reference will be available for collection as set out in the section entitled "*General Information – Documents Available*" in the Offering Circular (at pages 910-911) and on the Luxembourg Stock Exchange's website at www.bourse.lu.

Incorporation by Reference of BAC 28 October 2022 Form 10-Q

The BAC Form 10-Q dated 28 October 2022 in respect of the nine months ended 30 September 2022 (the "**BAC 28 October 2022 Form 10-Q**") was filed with the United States Securities and Exchange Commission (the "**SEC**") on 28 October 2022. By virtue of this Supplement, the sections of the BAC 28 October 2022 Form 10-Q referred to below are incorporated by reference into, and form part of, the Offering Circular. Any information included in the BAC 28 October 2022 Form 10-Q that is not listed below shall not be deemed to be incorporated by reference into, and form part of, this Supplement and is given for information purposes only.

Information Incorporated by Reference
From the BAC 28 October 2022 Form 10-Q

Page Number

Part I

Item 1. Financial Statements

<i>Consolidated Statement of Income</i>	<i>Page 49</i>
<i>Consolidated Statement of Comprehensive Income</i>	<i>Page 49</i>
<i>Consolidated Balance Sheet</i>	<i>Page 50</i>
<i>Consolidated Statement of Changes in Shareholders' Equity</i>	<i>Page 51</i>
<i>Consolidated Statement of Cash Flows</i>	<i>Page 52</i>
<i>Notes to Consolidated Financial Statements</i>	<i>Page 53</i>
<i>1 – Summary of Significant Accounting Principles</i>	<i>Pages 53</i>
<i>2 – Net Interest Income and Noninterest Income</i>	<i>Page 54</i>
<i>3 – Derivatives</i>	<i>Pages 55 to 61</i>
<i>4 – Securities</i>	<i>Pages 62 to 64</i>
<i>5 – Outstanding Loans and Leases and Allowance for Credit Losses</i>	<i>Pages 65 to 75</i>
<i>6 – Securitizations and Other Variable Interest Entities</i>	<i>Pages 76 to 79</i>
<i>7 – Goodwill and Intangible Assets</i>	<i>Page 79</i>
<i>8 – Leases</i>	<i>Page 80</i>
<i>9 – Securities Financing Agreements, Collateral and Restricted Cash</i>	<i>Pages 80 to 82</i>
<i>10 – Commitments and Contingencies</i>	<i>Pages 82 to 85</i>
<i>11 – Shareholders' Equity</i>	<i>Page 85</i>
<i>12 – Accumulated Other Comprehensive Income (Loss)</i>	<i>Pages 85 to 86</i>
<i>13 – Earning Per Common Share</i>	<i>Page 86</i>
<i>14 – Fair Value Measurements</i>	<i>Pages 86 to 93</i>
<i>15 – Fair Value Option</i>	<i>Pages 93 to 94</i>
<i>16 – Fair Value of Financial Instruments</i>	<i>Page 95</i>
<i>17 – Business Segment Information</i>	<i>Pages 95 to 99</i>
<i>Glossary</i>	<i>Pages 100 to 101</i>
<i>Acronyms</i>	<i>Page 102</i>

Part II

<i>Executive Summary</i>	<i>Page 3</i>
<i>Recent Developments</i>	<i>Pages 3 to 4</i>
<i>Financial Highlights</i>	<i>Pages 5 to 7</i>
<i>Supplemental Financial Data</i>	<i>Pages 8 to 11</i>
<i>Business Segment Operations</i>	<i>Page 12</i>
<i>Consumer Banking</i>	<i>Pages 12 to 15</i>
<i>Global Wealth & Investment Management</i>	<i>Pages 16 to 17</i>
<i>Global Banking</i>	<i>Pages 18 to 20</i>
<i>Global Markets</i>	<i>Pages 20 to 22</i>
<i>All Other</i>	<i>Page 22</i>
<i>Managing Risk</i>	<i>Pages 22 to 23</i>
<i>Capital Management</i>	<i>Pages 23 to 27</i>
<i>Liquidity Risk</i>	<i>Pages 27 to 30</i>
<i>Credit Risk Management</i>	<i>Page 30</i>
<i>Consumer Portfolio Credit Risk Management</i>	<i>Pages 30 to 35</i>
<i>Commercial Portfolio Credit Risk Management</i>	<i>Pages 35 to 41</i>
<i>Non-U.S. Portfolio</i>	<i>Page 41</i>
<i>Allowance for Credit Losses</i>	<i>Pages 42 to 43</i>
<i>Market Risk Management</i>	<i>Page 44</i>
<i>Trading Risk Management</i>	<i>Pages 44 to 45</i>

<i>Interest Rate Risk Management for the Banking Book</i>	<i>Pages 45 to 46</i>
<i>Mortgage Banking Risk Management</i>	<i>Pages 46 to 47</i>
<i>Climate Risk Management</i>	<i>Page 47</i>
<i>Complex Accounting Estimates</i>	<i>Page 47</i>
<i>Non-GAAP Reconciliations</i>	<i>Page 48</i>
<i>Item 3. Quantitative and Qualitative Disclosures about Market Risk</i>	<i>Page 48</i>
<i>Item 4. Controls and Procedures</i>	<i>Page 48</i>
Part II Other Information	
<i>Item 1. Legal Proceedings</i>	<i>Page 103</i>
<i>Item 1A. Risk Factors</i>	<i>Page 103</i>
<i>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</i>	<i>Page 103</i>
<i>Item 5. Other Information</i>	<i>Page 103</i>
<i>Item 6. Exhibits</i>	<i>Page 104</i>
<i>Signature</i>	<i>Page 104</i>